Drug intelligence / Profile preview

KIS siRNA

Development stage
Unknown
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Variable (dependent On Formulation; Typical Routes For siRNA Include Intravenous, Subcutaneous, Or Local Injection)
01

Overview

KIS siRNA refers to a small interfering RNA molecule specifically designed to silence the **KIS gene** (Kinase Interacting with Stathmin, also known as CDKN1B-interacting protein), utilizing the RNA interference (RNAi) pathway. siRNAs are synthetic double-stranded RNA molecules, generally 20–24 nucleotides in length, that post-transcriptionally silence gene expression by guiding the RNA-induced silencing complex (RISC) to degrade mRNA with a fully complementary sequence. The antisense (guide) strand of the siRNA mediates the sequence-specific degradation of the target mRNA, thereby preventing translation and ultimately reducing protein production[1][2][3][4][5][6][7]. KIS siRNA would be a sequence-specific agent for research or therapeutic applications seeking to downregulate KIS expression through targeted mRNA degradation. The precise design and specificity minimize off-target effects and make siRNA a potent tool for gene knockdown in research or potential clinical applications.

Other names
KIS siRNA
02

Targets

UHMK1 (U2AF homology motif kinase 1)

Beyond the preview

Go deeper on KIS siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIS siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call